Quinapril Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 5 mg, 10 mg, 20 mg, 40 mg
Reference Brands: Accupril (USA), Accupro (EU)
Category:
Heart Disorder
Quinapril is available in Tablets
and strengths such as 5 mg, 10 mg, 20 mg, 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Quinapril is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Quinapril can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Quinapril is an angiotensin-converting enzyme inhibitor (ACEi) developed in the 1980s, primarily used for the management of hypertension, a major risk factor for coronary heart disease. By inhibiting the action of angiotensin-converting enzyme (ACE), quinapril reduces the formation of angiotensin II, a potent vasoconstrictor, thereby relaxing blood vessels, lowering blood pressure, and reducing the workload on the heart. It is classified as a non-sulfhydryl ACE inhibitor and plays a vital role in modulating the renin-angiotensin-aldosterone system (RAAS).
In addition to its approved use for hypertension, quinapril is also prescribed off-label for managing chronic heart failure (CHF) and for slowing the progression of renal disease in patients with diabetes. Clinical studies have shown that quinapril effectively lowers systolic blood pressure by approximately 13 mm Hg and diastolic blood pressure by around 10 mm Hg in about two-thirds of treated individuals. Dosage may be adjusted based on patient response, tolerance, and clinical goals. Quinapril provides a well-established and effective option for long-term cardiovascular management, helping to reduce complications associated with high blood pressure and supporting overall heart and kidney health.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing